The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

Also called NCT01624207

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 376 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01624207
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01624207. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2011-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safety of Atorva® 20mg Versus Lipitor® 20mg
Condition
Hypercholesterolemia
Intervention (Drug)
generic formulation of atorvastatin (Atorva®)
Intervention (Drug)
branded formulation of atorvastatin (Lipitor®)
Lead sponsor
Seoul National University Hospital (class: other)
Collaborator
Yuhan corp., Seoul, Korea (class: not stated)

Record details

Record id
cardio:ct-nct01624207
Content hash
988083cd14e70001f34345f66a1c570e45ce56f179749df45203065d64a00bd2